New Low Stock Aibo Medical Shareholders Plan to Reduce Holdings; Accumulated Fundraising of 1.17 Billion IPO China Merchants Securities as Sponsor

China Economic Net Beijing, March 19 — AiBo Medical (688050.SH) announced last night a plan for shareholders to reduce their holdings. The company recently received a notice from shareholder Mao Liping regarding the reduction plan for AiBoNuoDe (Beijing) Medical Technology Co., Ltd. Mao Liping plans to reduce his holdings through block trades by no more than 1,934,000 shares, representing no more than 1% of the company’s total share capital. The implementation will occur within three months after the announcement, from April 10, 2026, to July 9, 2026.

As of the disclosure date, shareholder Mao Liping held 5,604,413 shares, accounting for 2.90% of the total share capital. Along with his concerted parties Bai Ying, they hold a total of 11,304,459 shares, representing 5.85% of the total. The shares held by Mao Liping include those acquired before the IPO and shares obtained through capital reserve dividends converted into shares after listing. These shares were listed and tradable on July 31, 2023, and June 5, 2024, respectively.

Today, AiBo Medical’s intraday lowest stock price was 53.00 yuan, setting a new low since listing.

AiBo Medical was listed on the STAR Market of the Shanghai Stock Exchange on July 29, 2020, with an issuance of 26.29 million shares at a price of 33.55 yuan per share. The sponsor was China Merchants Securities Co., Ltd.

The total fundraising amount was 882 million yuan, with a net amount of 804 million yuan after deducting issuance costs. The final net proceeds exceeded the original plan by 3.7865 million yuan. According to the company’s prospectus, AiBo Medical planned to raise 800 million yuan, which would be used for expanding capacity and automation of ophthalmic lenses and related products, R&D of high-end ophthalmic medical devices and high-value consumables, marketing network and information system construction, and working capital supplementation.

The issuance costs amounted to 78.04 million yuan, with China Merchants Securities earning 61.74 million yuan in sponsorship and underwriting fees.

According to the approval from the China Securities Regulatory Commission (CSRC) document “CSRC Permit [2025] No. 774,” the company conducted a simplified issuance to specific targets, issuing 3,593,615 shares at 79.20 yuan per share, raising a total of 284,614,308 yuan. After deducting issuance expenses of 4,001,997.70 yuan, the net proceeds were 280,612,310.30 yuan. All funds were received by April 25, 2025, and verified by ShineWing Certified Public Accountants (Special General Partnership) in their verification report “XYZH/2025BJAA12B0200” dated April 29, 2025.

In total, the two fundraising rounds raised approximately 1.167 billion yuan.

(责任编辑：华青剑)